TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists and other healthcare providers involved in the treatment of lung, colorectal and ovarian cancers.

OVERVIEW OF ACTIVITY
The clinical care of patients with incurable solid tumors is a challenging dilemma that practicing oncologists confront on a daily basis. Despite the existence of evidence-based treatment guidelines, many areas of inconsistency persist within academic and community settings. Given the heightened emphasis across oncology on the provision of high-quality care, endeavors designed to fill the resulting performance gaps are greatly needed.

The morbidity and mortality conference model traditionally evaluates disease management and potential areas for quality improvement. This program uses the model to gain insight into how patients who recently died of non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and ovarian cancer (OC) were cared for during their metastatic disease course and how specific approaches used align with evidence-based guidelines. Featuring information on the latest clinical and research developments along with expert perspectives, this activity is designed to assist medical oncologists with the formulation of up-to-date strategies for the long-term care of patients with metastatic NSCLC, CRC and OC.

LEARNING OBJECTIVES

• Identify opportunities to foster shared decision-making and heighten the engagement and satisfaction of patients and family members throughout the cancer care journey.
• Evaluate the current variability in the integration of specific agents, regimens and therapeutic approaches into the care of patients with metastatic NSCLC, CRC and OC, and use the input of clinical investigators to formulate optimal treatment strategies.
• Recall the scientific rationale for and emerging efficacy data with novel agents or therapeutic approaches in NSCLC and OC, and counsel appropriately selected patients about study participation.
• Implement a plan of care to prevent and ameliorate toxicities associated with existing and investigational therapies used in the management of advanced CRC.
• Recognize the benefits of early palliative care for patients with metastatic disease, and integrate this information, as appropriate, into current clinical treatment algorithms.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

LUNG CANCER FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Clinical Investigator

Heather Wakelee, MD
Associate Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California

Consulting Agreements: ACEA Biosciences Inc, Genentech BioOncology, Helsinn Group, Peregrine Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Xcovery; Grants: Clovis Oncology, Exelixis Inc, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Xcovery. 

General Oncologists

Maria Picton, MD
Physicians East
Greenville, North Carolina

No relevant conflicts of interest to disclose.

Estelamari Rodriguez, MD, MPH
Medical Director, Thoracic Oncology
Chair, Women’s Centered Care Network
Mount Sinai Medical Center
Comprehensive Cancer Center
Miami Beach, Florida

Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Speakers Bureau: Merck. 

COLORECTAL CANCER FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Clinical Investigator

J Randolph Hecht, MD
Professor of Clinical Medicine
Director, UCLA GI Oncology Program
Carol and Saul Rosenzweig Chair in Cancer Therapies Development
Santa Monica, California

Consulting Agreements: Amgen Inc, Genentech BioOncology, Roche Laboratories Inc. 

General Oncologists

Gigi Qiqi Chen, MD
Diablo Valley Oncology and Hematology Medical Group
Pleasant Hill, California 

Advisory Committee: Bayer HealthCare Pharmaceuticals; Speakers Bureau: Boehringer Ingelheim Pharmaceuticals Inc. 

Margaret Deutsch, MD
Clinical Associate — Medical Oncology
Duke Cancer Institute
Duke Cancer Center Raleigh
Raleigh, North Carolina

No relevant conflicts of interest to disclose.

OVARIAN CANCER FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Clinical Investigator

Michael Birrer, MD, PhD
Director, UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Advisory Committee: Acceleron Pharma, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc, Merrimack Pharmaceuticals Inc, OXiGENE Inc, Roche Laboratories Inc, Sanofi Genzyme, Threshold Pharmaceuticals. 

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech BioOncology and Lilly.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: July 2017
Expiration date: July 2018